CALCA and neuroendocrine neoplasm: These in vivo results suggest that the combination of Sulfatinib and Kaempferol preserves its therapeutic effectiveness in tumors deficient in CALCA, thereby offering critical preclinical insights for targeting aggressive neuroendocrine tumors characterized by CALCA genetic alterations.